163 related articles for article (PubMed ID: 37220335)
1. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.
Hamid AA; Sayegh N; Tombal B; Hussain M; Sweeney CJ; Graff JN; Agarwal N
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390166. PubMed ID: 37220335
[TBL] [Abstract][Full Text] [Related]
2. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract][Full Text] [Related]
3. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
5. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
7. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
8. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
[TBL] [Abstract][Full Text] [Related]
9. Whole blood
Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
[TBL] [Abstract][Full Text] [Related]
10. Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Reichert ZR; Kasputis T; Nallandhighal S; Abusamra SM; Kasputis A; Haruray S; Wang Y; Williams S; Singhal U; Alva A; Cackowski FC; Caram MEV; Palmbos PL; Yentz SE; Smith DC; Alumkal JJ; Morgan TM
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008431
[TBL] [Abstract][Full Text] [Related]
11. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
[TBL] [Abstract][Full Text] [Related]
14. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
Crawford ED; Andriole G; Freedland SJ; Garnick M; Gomella LG; Henderson J; Higano CT; Kader AK; Kane C; Keane TE; Koo PJ; Petrylak DP; Reiter RE; Slovin SF; Yu EY
Can J Urol; 2020 Oct; 27(5):10352-10362. PubMed ID: 33049187
[TBL] [Abstract][Full Text] [Related]
15. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
16. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract][Full Text] [Related]
17. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
[No Abstract] [Full Text] [Related]
18. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract][Full Text] [Related]
19. New drug approvals in prostate cancer and their effect on the treatment landscape.
Jani C; Abdallah N; Chrysafi P; Mouchati C; Herchenhorn D; McKay RR
Clin Adv Hematol Oncol; 2023 Jun; 21(6):321-340. PubMed ID: 37530638
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Pelloux-Prayer R; Schiele P; Oudard S; Gravis G; Kleinclauss F; Crehange G; Hennequin C; Morgans AK; Geoffrois L; Limat S; Thiery-Vuillemin A; Nerich V
Clin Genitourin Cancer; 2021 Oct; 19(5):e326-e333. PubMed ID: 33962909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
